Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Alicorp S.A.A. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to to assess the glycemic index and the satiating properties of different Quinoa varieties, using a Visual Analogue Scale in a sample of healthy overweight subjects.
Pilot study to evaluate the glycemic index, and the satiating effect using different Quinoa varieties in a group of healthy overweight subjects.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Quinoa variety 1 | Experimental | 1 dose of Quinoa Variety 1 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product. |
|
| Quinoa variety 2 | Experimental | 1 dose of Quinoa Variety 2 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product. |
|
| Quinoa variety 3 | Experimental | 1 dose of Quinoa Variety 3 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product. |
|
| Quinoa variety 4 | Experimental | 1 dose of Quinoa Variety 4 orally. The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the experimental powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Quinoa variety 1 | Dietary Supplement | On the intervention day, the volunteers will consume the Quinoa Variety 1. Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
|
| Measure | Description | Time Frame |
|---|---|---|
| Glycemic index | The glycemic index is calculated with the incremental area under the curve of the glycemic response 7 time points ( 0 , 15 , 30, 45 , 60, 90 , 120 min) to 50 g intake carbohydrate food test food and reference | 0, 15, 30, 45, 60, 90, 120 min |
| Measure | Description | Time Frame |
|---|---|---|
| Glucose metabolism related parameters | glucose and insulin assessed in 7 point curves | day 1, 8, 15, 22, 29 |
| satiety hunger assessment (visual analogue scale) | visual analogue scale to assessment satiety and hunger will be picked up in 9 time points to calculate the area under the curve to get a score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Carmen Gómez Candela, MD, PhD | La Paz University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitairo La Paz | Madrid | Madrid | 28046 | Spain |
Not provided
| Label | URL |
|---|---|
| La Paz University Hospital Research Institute | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D050177 | Overweight |
| ID | Term |
|---|---|
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
Not provided
Not provided
| ID | Term |
|---|---|
| D005947 | Glucose |
| ID | Term |
|---|---|
| D006601 | Hexoses |
| D009005 | Monosaccharides |
| D000073893 | Sugars |
| D002241 | Carbohydrates |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Anhydrous Glucose | Active Comparator | 1 dose of Anhydrous Glucose orally. . The product is provided in a mix-pack together with water (100mL). This flexible container is capable of maintaining separate purified water (100 mL) and the control powder product in the same package. Both products can be easily mixed by breaking the inner seal. Volunteers had a maximum of 10 minutes to consume the product. |
|
|
| Quinoa variety 2 | Dietary Supplement | On the intervention day, the volunteers will consume the Quinoa Variety 2. Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
|
|
| Quinoa variety 3 | Dietary Supplement | On the intervention day, the volunteers will consume the Quinoa Variety 3. Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
|
|
| Quinoa variety 4 | Dietary Supplement | On the intervention day, the volunteers will consume the Quinoa Variety 4. Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
|
|
| Anhydrous Glucose | Dietary Supplement | On the intervention day, the volunteers will consume the control product. Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
|
|
| just before taking the product, just after taking the product, 30, 60 , 90, 120, 180, 240 min and 260 min after taking the product) |
| Weight | Weight | day 1, 8, 15, 22, 29 |
| Adverse effects | symptoms of gastrointestinal intolerance (nausea, diarrhea, bloating or other gastrointestinal disorder | day 1, 8, 15, 22, 29 |
| Blood hormonal markers | ghrelin, GLP-1 (glucagon-like peptide) and peptide YY | just before taking the product, 15, 30, 45, 60, 90 and 120 min after consuming the product |
| height | day 1, 8, 15, 22, 29 |
| waist circumference | day 1, 8, 15, 22, 29 |
| BMI | body mass index | day 1, 8, 15, 22, 29 |
| D012816 |
| Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |